Key terms
About LPTX
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LPTX news
Mar 19
6:48am ET
Leap Therapeutics price target lowered to $9 from $11 at Baird
Mar 19
6:19am ET
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
Mar 19
2:00am ET
Leap Therapeutics’ Success Tied to Partner NovaRock’s Commitment in Asian Markets
Mar 18
7:42am ET
Leap Therapeutics files $200M mixed securities shelf
Mar 18
7:01am ET
Leap Therapeutics reports Q4 EPS (46c), consensus (55c)
Jan 26
12:49am ET
Maintaining Buy Rating on Leap Therapeutics: Promising DKN-01 Trials and Undervalued Market Potential
Jan 26
12:42am ET
Analysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Leap Therapeutics (LPTX)
Jan 26
12:40am ET
Outperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial Outcomes
Jan 24
6:41am ET
Analysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)
Jan 22
3:50pm ET
Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO)
Jan 22
2:50pm ET
Leap Therapeutics (LPTX) Gets a Buy from Piper Sandler
No recent news articles are available for LPTX
No recent press releases are available for LPTX
LPTX Financials
Key terms
Ad Feedback
LPTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LPTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range